Abstract
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep-onset rapid eye movement (REM) sleep periods. Narcolepsy is now identified to be a neurodegenerative disease, as there is a massive loss of neurons containing the neuropeptide, hypocretin/orexin. Orexin neurons are solely located in the hypothalamus, particularly in its perifornical, dorsomedial and lateral portions. Orexin fibers widely project throughout the brain and generally have excitatory effects on their postsynaptic cells. Patients with narcolepsy have a severe reduction in the levels of orexins in the cerebrospinal fluid, a finding consistent with orexin neuronal loss. Experimental models have been generated in order to study the physiology of the orexin system and narcolepsy. The discovery of orexin deficiency in narcolepsy is redefining the clinical entity of narcolepsy and offering novel diagnostic procedures. This article reviews the current understanding of narcolepsy and discusses the opportunity to explore the potential use of transplants as a therapeutical tool in order to treat narcolepsy.
Keywords: hypocretin/orexin neurons, narcolepsy, sleep, lateral hypothalamus, animal models, cell transplant
CNS & Neurological Disorders - Drug Targets
Title: Cell Transplantation: A Future Therapy for Narcolepsy?
Volume: 8 Issue: 4
Author(s): Oscar Arias-Carrion and Eric Murillo-Rodriguez
Affiliation:
Keywords: hypocretin/orexin neurons, narcolepsy, sleep, lateral hypothalamus, animal models, cell transplant
Abstract: Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep-onset rapid eye movement (REM) sleep periods. Narcolepsy is now identified to be a neurodegenerative disease, as there is a massive loss of neurons containing the neuropeptide, hypocretin/orexin. Orexin neurons are solely located in the hypothalamus, particularly in its perifornical, dorsomedial and lateral portions. Orexin fibers widely project throughout the brain and generally have excitatory effects on their postsynaptic cells. Patients with narcolepsy have a severe reduction in the levels of orexins in the cerebrospinal fluid, a finding consistent with orexin neuronal loss. Experimental models have been generated in order to study the physiology of the orexin system and narcolepsy. The discovery of orexin deficiency in narcolepsy is redefining the clinical entity of narcolepsy and offering novel diagnostic procedures. This article reviews the current understanding of narcolepsy and discusses the opportunity to explore the potential use of transplants as a therapeutical tool in order to treat narcolepsy.
Export Options
About this article
Cite this article as:
Arias-Carrion Oscar and Murillo-Rodriguez Eric, Cell Transplantation: A Future Therapy for Narcolepsy?, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921681
DOI https://dx.doi.org/10.2174/187152709788921681 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages
Current Alzheimer Research Ferulic Acid and Alzheimer’s Disease: Promises and Pitfalls
Mini-Reviews in Medicinal Chemistry Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Clinical Application of the Vestibular Stimulation Effect on Balance Disorders with Dementia
Current Alzheimer Research The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases
Current Pharmaceutical Design The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Commentary: Research Highlights ATF4: The Perpetrator in Axonal-Mediated Neurodegeneration in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Protein Aggregation and Its Consequences for Human Disease
Protein & Peptide Letters Involvement of Rat Hippocampal Astrocytes in β-Amyloid-Induced Angiogenesis and Neuroinflammation
Current Alzheimer Research A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Lipids as Delivery Systems to Improve the Biological Activity of Bioactive Ingredients
Current Nutrition & Food Science Editorial [Hot Topic: New Developments in Therapy for Oxidative Stress-Related Diseases: Pathophysiological and Clinical Consequences (Executive Guest Editor: Victor M. Victor)]
Current Pharmaceutical Design Agents Complexing Copper as a Therapeutic Strategy for the Treatment of Alzheimers Disease
Current Alzheimer Research Does Human Alpha-Synuclein Behave Like Prions?
CNS & Neurological Disorders - Drug Targets Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry